Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 13/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 12/20 | 0.48 |
| ▸ | NQO2 | P16083 | 11/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.42 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101693 | 0.85 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL5095627 | 0.80 | ESR1 (0.69) | MTNR1AMTNR1BNQO2TRPV1ESR1 | |
| SCHEMBL2667002 | 0.79 | MTNR1A (0.59) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL2877992 | 0.74 | CYP26A1 (0.76) | CYP26A1CYP24A1 | |
| SCHEMBL1928327 | 0.73 | STS (0.65) | — | |
| SCHEMBL2387203 | 0.73 | MEN1 (0.37) | — | |
| SCHEMBL2387207 | 0.73 | MEN1 (0.37) | — | |
| SCHEMBL3101298 | 0.73 | SLC6A9 (0.50) | DRD2HTR1DDRD3TRPV1 | |
| SCHEMBL2875252 | 0.72 | MTNR1A (0.43) | MTNR1AMTNR1BNQO2TRPV1ESR1 | |
| SCHEMBL3316267 | 0.70 | STS (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318760-B2 | Type 2 diabetes, atherosclerosis; compounds are N-(2-carboxyethyl)benzamides or N-tetrazolyl derivatives of benzamides; glucagon antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | MERCK & CO., INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2006102067-A1 | SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES | MERCK & CO., INC. (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161347-A1 | Substituted Aryl and Heteroaryl Derivatives, Compositions Containing Such Compounds and Methods of Use | GPR119, PNLIP, SLC5A2 | MTNR1A 424/4885MTNR1B 142/4885NQO2 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.